BioRestorative Therapies, Inc. - Common Stock (BRTX)

MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032, growing at a CAGR of 13.34% between 2024 and 2032. Medical aesthetics, a subsection of the global aesthetics market, was estimated to be worth $15.4 billion in 2023 and is expected to reach $25.9 billion by 2028 at a CAGR of 11%. BioRestorative Therapies Inc. (NASDAQBRTX) intends to elaborate on this commercial platform in connection with its Q1 filing, along with a general business update.

MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQBRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its lead therapeutic candidate for the treatment of patients with chronic lower back pain caused by degenerative disc disease. According to experts, up to 80% of the population will experience back pain at some point. This technology involves using the patient's own stem cells to regenerate damaged discs in the lower back, potentially reducing pain and improving mobility.

MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQBRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its lead therapeutic candidate for the treatment of patients with chronic lower back pain caused by degenerative disc disease. This technology involves using the patient's own stem cells to regenerate damaged discs in the lower back, potentially reducing pain and improving mobility. BioRestorative is also developing ThermoStem(R), an off-the-shelf cell-based therapeutic designed to help people with metabolic disorders such as obesity and diabetes.

MELVILLE, NY / ACCESSWIRE / August 30, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Back pain can exist alone without nerve involvement and oftentimes, this is the most painful type of chronic pain. Additionally, spinal discs naturally degenerate with age, and as such, many people experience chronic back pain for no reason other than aging.

MELVILLE, NY / ACCESSWIRE / August 2, 2023 / Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying - the "smart money" - can also be an indicator to evaluate the potential performance of a company. BioRestorative Therapies Inc. (NASDAQBRTX) ("BioRestorative") insiders are expressing their confidence in the company's future. Dale Broadrick, an insider of the company, has demonstrated this faith by acquiring 1,000 shares of BioRestorative. These purchases were made at a price of an average of $2.80 per share on July 27, 2023. As a result, Broadrick now owns a total of 623,404 shares of the company.

MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point. BioRestorative Therapies Inc. (NASDAQBRTX) ("BioRestorative") recently held a virtual panel about their stem cell-based therapies and one of the first things that Dr. Jason Lipetz, an expert panelist, shared was that the current state of treatment for chronic back pain "is an embarrassment for the world of spine care."

MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQBRTX) ("BioRestorative"), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank. The license enables BioRestorative to process mesenchymal stem cells obtained from autologous donors. BioRestorative is now the first facility in New York State to be licensed to process mesenchymal stem cells for clinical use, setting the company apart from competitors in the field.

MELVILLE, NY / ACCESSWIRE / July 7, 2023 / BioRestorative Therapies Inc. (NASDAQBRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100. The independent review body Data Safety Monitoring Board (DSMB) which is overseeing dose and safety related issues during the course of the trial approved the trial's continuation with no changes to the current version of the protocol.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

MELVILLE, NY / ACCESSWIRE / June 15, 2023 / Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise.

MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to address several medical conditions, including metabolic disorders such as Obesity, Type 2 Diabetes, Hypertension and other metabolic diseases which capture multi-billion dollar market opportunities. Brown fat has been shown to regulate metabolic homeostasis in the body, creating heat and regulating key functions. This therapy harnesses the body's healing mechanism through stem cells derived from brown adipose tissue. Brown Adipose-derived stem cell therapy is considered a safe procedure and reduces the risks and complications of surgery.

BioRestorative Therapies (NASDAQBRTX) ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

By Julian Richard, Benzinga

By Julian Richard, Benzinga

BioRestorative Therapies (NASDAQBRTX), a clinical-stage company focused on stem cell-based therapies, has received a notice of allowance for the patent application relating to its metabolic ThermoStem(R) program. The notice, dated Feb. 24, 2023, came from the United States Patent and Trademark Office. This marks the third patent approved relating to this specific group of intellectual property, the company noted; the new patent covers three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells, which have exhibited potential to be a valuable therapeutic tool for treating a range of metabolic disorders. The company also indicated that it is exploring options for using this technology to target indications outside of metabolic disorders. “This is the second notice of allowance we have received regarding our ThermoStem program within 2023,” said BioRestorative Therapies CEO Lance Alstodt in the press release. “This notice of allowance is very meaningful as it provides the company with further protection and strengthens our technology as we develop and expand into the clinic. Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities.”

By Julian Richard, Benzinga

BioRestorative Therapies (NASDAQBRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.”

By Julian Richard, Benzinga

By Faith Ashmore, Benzinga

--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome --

-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones--

BioRestorative Therapies (NASDAQBRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include seasoned institutional and accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients. Interested parties should visit https://ibn.fm/XMA3b to learn more and submit a registration request.

Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQBRTX),NASDAQ:MDXGNASDAQMDXG)(NYSE:NNVCNYSENNVC,(NASDAQ:VCELNASDAQ) EQNX::TICKER_END

BioRestorative Therapies Inc. (NASDAQBRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.